Actuarial survival from AML remission for the CCG-2891 patients who received intensive-timing induction therapy, comparing the 3 postremission regimens.

Numbers are patients at risk at yearly intervals; rows are in the same order as curves. P value is for homogeneity. Dashed line indicates allogeneic BMT; solid line, intensive non–marrow-ablative chemotherapy; dotted line, autologous BMT.